Details of the Drug

General Information of Drug (ID: DMM9BJD)

Drug Name
Tisagenlecleucel
Synonyms Tisagenlecleucel-T
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 3 [2]
Diffuse large B-cell lymphoma 2A81 Phase 3 [2]
Follicular lymphoma 2A80 Phase 2 [2]
Acute myeloid leukaemia 2A60 Application submitted [3]
ATC Code
L01XL04: Tisagenlecleucel
L01XL: Antineoplastic cell and gene therapy
L01X: OTHER ANTINEOPLASTIC AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
CAR T Cell Therapy
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 9.91 days []
Half-life
The concentration or amount of drug in body reduced by one-half in 16.8 days []
Cross-matching ID
UNII
Q6C9WHR03O
DrugBank ID
DB13881
TTD ID
D0IM6T
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN Immunostimulant [1]
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN Immunostimulant [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)